Clinical Trial

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Study acronym: TONIC-3
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-25; most recent amendment 2024-09-10.
Status change: Not Yet Recruiting → Recruiting 2024-06-13
Trial Details
NCT Number NCT06342037
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Hoffmann-La Roche
Conditions Metastatic Breast Cancer
Enrollment 60 participants
Start Date 2024-06-12
Primary Completion 2026-04-01 (estimated)
Study Completion 2030-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19